...
首页> 外文期刊>Acta pharmaceutica: a quarterly journal of Croatian Pharmaceutical Society and Slovenian Pharmaceutical Society, dealing with all branches of pharmacy and allied sciences >Formulation development of oral controlled release tablets of hydralazine: optimization of drug release and bioadhesive characteristics.
【24h】

Formulation development of oral controlled release tablets of hydralazine: optimization of drug release and bioadhesive characteristics.

机译:肼苯哒嗪口服控释片的制剂开发:药物释放和生物粘附特性的优化。

获取原文
获取原文并翻译 | 示例

摘要

The current study involves development of oral bioadhesive hydrophilic matrices of hydralazine hydrochloride, and optimization of their in vitro drug release profile and ex vivo bioadhesion against porcine gastric mucosa. A 32 central composite design was employed to systematically optimize the drug delivery formulations containing two polymers, viz., carbomer and hydroxypropyl methyl cellulose. Response surface plots were drawn and optimum formulations were selected by brute force searches. Validation of the formulation optimization study indicated a very high degree of prognostic ability. The study successfully undertook the development of an optimized once-a-day formulation of hydralazine with excellent bioadhesive and controlled release characteristics.
机译:当前的研究涉及盐酸肼屈嗪的口服生物粘附性亲水性基质的开发,以及它们的体外药物释放特性和对猪胃粘膜的离体生物粘附性的优化。采用32位中央复合材料设计来系统优化包含两种聚合物(即卡波姆和羟丙基甲基纤维素)的药物输送配方。绘制响应面图,并通过蛮力搜索选择最佳配方。配方优化研究的验证表明预后能力非常高。该研究成功地开发了具有出色生物粘附力和控释特性的优化的肼苯哒嗪每日一次制剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号